Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain DVAX message board posts where the ticker symbol DVAX has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest DVAX SEC Filings

Filings Format Description Filing Date File/Film Number
S-8  Documents Securities to be offered to employees in employee benefit plans
Acc-no: 0001193125-17-357411 (33 Act)  Size: 95 KB
2017-11-30 333-221832
171231773
8-K  Documents Current report, items 5.02 and 9.01
Acc-no: 0001193125-17-357364 (34 Act)  Size: 199 KB
2017-11-30 001-34207
171231594
8-K  Documents Current report, items 1.01, 8.01, and 9.01
Acc-no: 0001193125-17-342558 (34 Act)  Size: 45 KB
2017-11-14 001-34207
171201559
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001193125-17-332908 (34 Act)  Size: 80 KB
2017-11-03 001-34207
171176965
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-17-332832 (33 Act)  Size: 327 KB
2017-11-03 333-219781
171176664
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001564590-17-021523 (34 Act)  Size: 6 MB
2017-11-03 001-34207
171176463
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001193125-17-275616 (34 Act)  Size: 69 KB
2017-09-01 001-34207
171066392
8-K  Documents Current report, items 1.01, 8.01, and 9.01
Acc-no: 0001193125-17-254482 (34 Act)  Size: 238 KB
2017-08-10 001-34207
171021660
424B5  Documents Prospectus [Rule 424(b)(5)]
Acc-no: 0001193125-17-254466 (33 Act)  Size: 365 KB
2017-08-10 333-219781
171021632
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001623632-17-001765 (34 Act)  Size: 277 KB
2017-08-09 005-80035
171018454
More DVAX SEC Filings


Related news from
Tue, 05 Dec 2017
21:01:00 +0000
Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dynavax Technologies Corporation today announced that on November 28, 2017 the Compensation Committee of Dynavax's Board of Directors approved the grant of inducement stock options to purchase an aggregate ...
Tue, 28 Nov 2017
12:50:00 +0000
Report: Exploring Fundamental Drivers Behind Starbucks, Home Depot, Kroger, Dynavax Technologies, Kratos Defense & Security Solutions, and Medtronic — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 28, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Starbucks ...
Mon, 27 Nov 2017
21:01:00 +0000
Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
Dynavax Technologies Corporation announced today that Eddie Gray, Dynavax's chief executive officer, will present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference this week in Boston, MA. The ...
Mon, 13 Nov 2017
13:10:00 +0000
Today’s Research Reports on Stocks to Watch: Dynavax Technologies and Puma Biotechnology
NEW YORK, NY / ACCESSWIRE / November 13, 2017 / Shares of Dynavax soared almost 18% in pre-market trading on Friday after the company announced its Hepislav-B vaccine for Hepatitis B was approved by the ...
Sun, 12 Nov 2017
23:49:32 +0000
Cowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine Market
Dynavax Technologies (NASDAQ:DVAX) after five years of "torturous" waiting has at long last garnered FDA approval for Heplisav-B. Cowen analyst Phil Nadeau anticipates hundreds of millions of dollars to be made in the HBV vaccine market within 5 years.
Sun, 12 Nov 2017
17:51:56 +0000
Third time’s the charm: Dynavax shares rocket 18% on hepatitis B vaccine approval
The vaccine is then first new hepatitis B one in the U.S. in decades and should be a lot more convenient to get.
Sat, 11 Nov 2017
12:23:00 +0000
It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval
Sure, Dynavax has already chalked up huge gains. But there's still room for the biotech stock to go higher.
Fri, 10 Nov 2017
13:44:17 +0000
At Long Last, Dynavax Wins FDA Approval For Heplisav
Dynavax Technologies Corporation (NASDAQ: DVAX ), a clinical-stage immunotherapy company, confirmed on Thursday the U.S. Food and Drug Administration approved its two-dose vaccine  The company failed to ...
Fri, 10 Nov 2017
12:19:17 +0000
Dynavax stock surges 18% on hepatitis B vaccine approval
Dynavax Technologies Corporation shares surged 18% in premarket trade Friday after the company said its hepatitis B vaccine was approved by the Food and Drug Administration. The vaccine, Hepislav-B, is ...
Thu, 09 Nov 2017
22:44:45 +0000
Third time's the charm: East Bay drug maker wins FDA approval for hepatitis B vaccine
An easier-to-take vaccine from an East Bay company, which could shift the fight against the surging, deadly hepatitis B virus, won regulatory approval Thursday. The company has spent hundreds of millions of dollars trying to develop the vaccine over more than a dozen years. The FDA rejected Heplisav B in February 2013 and delayed approval a year ago in order to study late-arriving data more closely.
Thu, 09 Nov 2017
22:12:53 +0000
Dynavax Technologies Corporation’s (DVAX) Hepatitis B Vaccine Wins FDA Approval
Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S. Food and Drug Administration approval for its hepatitis B vaccine, HEPLISAV, ending a more than nine-year effort to bring the vaccine to the market. Dynavax shares reacted to the FDA approval, rising nearly 16% to $23.25 in after-hours trading. Hepatitis B is an extremely infectious and potentially deadly virus affecting a wide range of adults in the United States.
Thu, 09 Nov 2017
21:45:19 +0000
Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults
Dynavax Technologies Corporation today announced that the U.S. Food and Drug Administration has approved HEPLISAV-B for prevention of infection caused by all known subtypes ...
Thu, 09 Nov 2017
13:37:01 +0000
Options Traders Expect Huge Moves in Dynavax (DVAX) Stock
Dynavax (DVAX) needs investors to pay close attention to the stock based on moves in the options market lately.
Wed, 08 Nov 2017
22:58:20 +0000
ETFs with exposure to Dynavax Technologies Corp. : November 8, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dynavax Technologies Corp. Here are 5 ETFs with the largest exposure to DVAX-US. Comparing the performance and risk of Dynavax Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Wed, 08 Nov 2017
20:04:20 +0000
Dynavax Awaits FDA Verdict On Hepatitis B Vaccine
Undaunted by two earlier FDA snubs, Dynavax Technologies Corporation (NASDAQ: DVAX ) is trying again with its hepatitis B vaccine, Heplisav. Will it successfully scale the hurdle the third time? Investors ...
Wed, 08 Nov 2017
18:44:36 +0000
Dynavax Technologies Corp. breached its 50 day moving average in a Bullish Manner : DVAX-US : November 8, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Dynavax Technologies Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more <b>(Read more...)</b>
Fri, 03 Nov 2017
10:30:00 +0000
Dynavax Reports Third Quarter 2017 Financial Results
Dynavax Technologies Corporation today reported financial results for the third quarter ended September 30, 2017. Cash, cash equivalents and marketable securities were $191.7 million at September 30, 2017 ...
Thu, 19 Oct 2017
10:30:00 +0000
Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy
Dynavax Technologies Corporation announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 agonist, DV281, in patients with non-small ...
Thu, 12 Oct 2017
14:26:09 +0000
ETFs with exposure to Dynavax Technologies Corp. : October 12, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Dynavax Technologies Corp. Here are 5 ETFs with the largest exposure to DVAX-US. Comparing the performance and risk of Dynavax Technologies Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more <b>(Read more...)</b>
Thu, 05 Oct 2017
16:24:00 +0000
Two Techs And Two Biotechs Breaking Out
Here are two biotech and two tech stocks that are breaking out technically.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "VF is the place to be to pick up on new and proven investment ideas." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards